Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 30, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Sacubitril and Valsartan Tablets, 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 30, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Sacubitril and Valsartan Tablets, 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg.".